There are 2789 resources available
119O - Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized phase III trial
Presenter: Sibylle Loibl
Session: Proffered Paper session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
Introduction by the chair
Presenter: Clara Montagut Viladot
Session: Do we need full molecular profile upfront in all CRC patients in daily practice?
Resources:
Slides
Webcast
Yes
Presenter: Sara Lonardi
Session: Do we need full molecular profile upfront in all CRC patients in daily practice?
Resources:
Slides
Webcast
Invited Discussant LBA11 and 117O
Presenter: Antonio Llombart Cussac
Session: Proffered Paper session - Breast cancer, early stage
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Antonio Llombart Cussac
Session: Proffered Paper session - Breast cancer, early stage
Resources:
Slides
Webcast
Invited Discussant 118O and 119O
Presenter: Monica Arnedos
Session: Proffered Paper session - Breast cancer, early stage
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Monica Arnedos
Session: Proffered Paper session - Breast cancer, early stage
Resources:
Slides
Webcast
Invited Discussant LBA23 and 512O
Presenter: Christophe Massard
Session: Proffered Paper session - Developmental therapeutics
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Christophe Massard
Session: Proffered Paper session - Developmental therapeutics
Resources:
Slides
Webcast
Invited Discussant 513O and 514O
Presenter: Elena Garralda
Session: Proffered Paper session - Developmental therapeutics
Resources:
Slides
Webcast